Human immune system response to Measles, Mumps, and Rubella viral antigens (MMR immune response)

The human immune system response to measles, mumps, and rubella (MMR) viral antigens represents a complex, multi-faceted physiological process rather than a single molecular target (StatPearls, 2023). Upon exposure to these live-attenuated viral antigens via vaccination, the innate immune system triggers an initial inflammatory response, which subsequently activates the adaptive immune system (CDC, 2021). This leads to the differentiation of B cells into plasma cells that produce virus-specific neutralizing antibodies (IgG and IgM) and the activation of CD4+ and CD8+ T cells (FDA, 2020). These components work together to provide long-term immunological memory, protecting the individual from future infections by the wild-type viruses. While the MMR vaccine is the primary pharmacological agent interacting with this system, the target in this context is the collective immune apparatus of the host. Understanding this response is critical for evaluating vaccine efficacy and safety, particularly in vulnerable populations (WHO, 2019).

Other names

MMR vaccine responseMeasles-Mumps-Rubella immunityAdaptive immunity to MMRMMR seroconversion

Induction of active immunity through the production of neutralizing antibodies and activation of T-lymphocytes against measles, mumps, and rubella viruses (StatPearls, 2023).